Ultrahypofractionation of localized prostate cancer

  • PDF / 318,232 Bytes
  • 8 Pages / 612.419 x 808.052 pts Page_size
  • 81 Downloads / 197 Views

DOWNLOAD

REPORT


REVIEW ARTICLE

Ultrahypofractionation of localized prostate cancer Statement from the DEGRO working group prostate cancer Frank Wolf1 · Felix Sedlmayer1 · Daniel Aebersold2 · Clemens Albrecht3 · Dirk Böhmer4 · Michael Flentje5 · Ute Ganswindt6 · Pirus Ghadjar4 · Stefan Höcht7 · Tobias Hölscher8 · Arndt-Christian Müller9 · Peter Niehoff10 · Michael Pinkawa11 · Nina-Sophie Schmidt-Hegemann12 · Constantinos Zamboglou13 · Daniel Zips9 · Thomas Wiegel14 Received: 12 November 2020 / Accepted: 17 November 2020 © The Author(s) 2020

Abstract Due to its low fractionation sensitivity, also known as “alpha/beta ratio,” in relation to its surrounding organs at risk, prostate cancer is predestined for hypofractionated radiation schedules assuming an increased therapeutic ratio compared to normofractionated regimens. While moderate hypofractionation (2.2–4 Gy) has been proven to be non-inferior to normal fractionation in several large randomized trials for localized prostate cancer, level I evidence for ultrahypofractionation (>4 Gy) was lacking until recently. An accumulating body of non-randomized evidence has recently been strengthened by the publication of two randomized studies comparing ultrahypofractionation with a normofractionated schedule, i.e., the Scandinavian HYPO-RT trial by Widmark et al. and the first toxicity results of the PACE-B trial. In this review, we aim to give a brief overview of the current evidence of ultrahypofractionation, make an overall assessment of the level of evidence, and provide recommendations and requirements that should be followed before introducing ultrahypofractionation into routine clinical use.

Keywords Extreme hypofractionation · Radiotherapy · Hypofractionation · SBRT · SABR

 Frank Wolf

[email protected] 1

Universitätsklinik für Radiotherapie und Radio-Onkologie, LKH, Universitätsklinikum, Paracelsus Medizinische Privatuniversität, Müllner Hauptstr. 48, 5020 Salzburg, Austria

7

Xcare Praxis für Strahlentherapie Saarlouis, Xcare Gruppe, Saarlouis, Germany

8

Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

9

Universitätsklinik für Radioonkologie, Universitätsklinikum Tübingen, Tübingen, Germany

10

Sana Klinikum Offenbach, Offenbach, Germany

11

MediClin Robert Janker Klinik, Bonn, Germany

Klinik für Radioonkologie und Strahlentherapie, Charité Universitätsmedizin, Berlin, Germany

12

Klinik für Radio-Onkologie, Universitätsklinikum der LMU, Munich, Germany

Klinik und Poliklinik für Strahlentherapie, Universitätsklinikum Würzburg, Würzburg, Germany

13

Klinik für Radio-Onkologie, Universitätsklinikum Freiburg, Freiburg, Germany

Universitätsklinik für Strahlentherapie-Radioonkologie, Innsbruck, Austria

14

Abteilung Strahlentherapie, Universitätsklinikum Ulm, Ulm, Germany

2

Universitätsklinik für Radio-Onkologie, Inselspital, Universität Bern, Bern, Switzerland

3

Klinik für Radioonkologie und Gemeinschaftspraxis für Strahlentherapie, Klinikum Nürnberg Nord, Univer